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Abstract 
Background: Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) is clinically characterized by the pres-
ence of exposed bone in the oral cavity that persists for more than eight weeks. Previous attempts to establish 
an animal model have not sufficiently considered disease features. Our aim was to establish an inexpensive and 
replicable animal model that develops BRONJ in a short time. 
Material and Methods: Thirty-two male Wistar rats were randomly divided into two groups: control and experi-
mental. In the experimental group, we administered 0.06mg/kg intraperitoneal dose of zoledronic acid (ZA) 7 and 
14 days prior to maxillary second molar extraction. At two, four and six weeks after tooth extraction, the animals 
were euthanized, and we dissected the maxilla following histological procedures. We stained serial slides with 
hematoxylin and eosin and Masson’s trichrome. The samples were harvested for macroscopic, radiologic and his-
tological evaluation of bone changes. 
Results: At two weeks postextraction, we observed exposed necrotic bone in dental socket areas in experimental 
groups. Radiological analysis revealed osteolytic lesions accompanied by extensive destruction and sequestrum 
formation in the same group. Histological examination confirmed the absence of necrotic bone in control groups 
in contrast with the experimental groups. The percentage of empty lacunae and the number of osteoclasts and the 
necrotic bone area were significantly increased (p<0.05) in the experimental groups. 
Conclusions: The animal model using ZA administration to prior dental extraction successfully mimicked hu-
man BRONJ lesions. Also, the model was easily replicated, inexpensive and showed different features than other 
previous BRONJ models. 
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Introduction
Bisphosphonates (BPs) represent a major class of antire-
sorptive drugs used in the prevention and treatment of 
osteoporosis, hypercalcemia of malignancy, multiple 
myeloma, Paget’s disease and bone metastases associat-
ed with breast, prostate, and lung, as well as osteogene-
sis imperfecta, fibrous dysplasia, and Gaucher’s disease 
(1,2). In afflicted patients, it effectively returns bone 
mineral density, reduces the incidence of bone fracture, 
and improves their quality of life. Despite these benefi-
cial effects, a growing number of patients on long-term 
and high-dose BP therapy develop a potentially serious 
complication: osteonecrosis of the jaw (3,4). 
BRONJ is defined clinically as an area of exposed bone 
in the maxillofacial region that does not heal within 
eight weeks in patients with no history of radiation 
therapy to the head and neck region. In this condition, 
the bone tissue in jaws often fails to heal following mi-
nor trauma, although it can also occur spontaneously 
(5-8). The most commonly reported symptoms of this 
condition are bone exposure, pain, bone sequestration, 
fistulas that extend from mucous membranes to the sur-
face of the skin, edema, paraesthesia and susceptibility 
to pathological bone fractures (9). However, in 90% of 
cases, it is caused by dental treatment of some kind. 
Most cases of BRONJ have been reported in patients 
receiving prolonged intravenous treatment of zoledro-
nate. BRONJ is rare in patients taking oral BPs for oste-
oporosis, and it is estimated between 0.001% and 0.1%. 
A recent study revealed an increased number of BRONJ 
cases, possibly owing to chronic oral BP use and thor-
ough screening (1,4,10).
Several research groups and medical societies have 
recently published recommendations or guidelines on 
prevention, staging, and management strategies for 
BRONJ (11). Despite this, there is still a lack of informa-
tion concerning the incidence, pathogenesis, treatment 
strategies, and prevention of BRONJ. 
Numerous BRONJ studies have been previously per-
formed on rats, but their results were inconsistent. For 
example, these researches have different protocols from 
the dose, interval, duration, route of administration 
of the BP medication to the use of co-medications for 
BRONJ induction had been used (12-17). Furthermore, 
in previous studies, their findings are not reliable and 
comparable, so the development of an inexpensive easi-
ly replicable experimental animal model is necessary to 
help to understand the physiopathology of BRONJ and 
eventually to establish preventive strategies and better 
treatment of this lesion. 
Our goal was to develop a clinically relevant, inexpen-
sive, and easily replicable animal model of Wistar rats 
treated with zoledronic acid and subjected to oral sur-
gery in the form of dental extraction.
Material and Methods
- Animals
We used thirty-two male Wistar rats (Rattus norvegi-
cus, albinus) weighing from 200-250g which were ob-
tained from the bioterium of the National Autonomous 
University’s Faculty of Higher Studies in Iztacala, Mex-
ico. The rats were housed in cages at an ambient tem-
perature (21°C-27°C) with a 12h light/dark cycle. Ani-
mals were fed a standard diet of rat chow and drink tap 
water ad libitum. The research protocol was conducted 
following the strict federal guidelines for the use and 
care of laboratory animals (NOM-062-ZOO-1999). The 
research protocol was submitted and approved by the 
Ethical Committee from Faculty of Superior Studies- 
Iztacala, National Autonomous University of Mexico, 
Mexico (PE209312).
- Study Design
We randomly divided the rats using a random number 
table into two groups (n=16 per group): the control and 
the experimental group. We divided the both study 
groups in three subgroups regarding the sacrificed mo-
ment: two weeks (n=6), four weeks (n=6) and six weeks 
(n=4) after dental extraction. An allocation concealment 
was performed.
- Study Procedures
- Dosage
We established the dose of zoledronic acid (Zometa®, 
Novartis Pharma©, Basel, Switzerland) at 0.06mg/kg, 
according to previous studies (18) and the experimen-
tal group was administered intramuscularly to the sev-
enth and fourteenth day before dental extraction. At the 
same time, the control rats received the same volume of 
saline solution.
- Dental extractions and post-surgical care
We extracted the second maxillary molar, as follows: We 
administrated intramuscularly animals previously anes-
thetized with ketamine (60mg/kg) and xylazine (7mg/kg), 
once verified sedation, we performed the oral disinfec-
tion and then we detached the gingiva around the second 
maxillary molar using a sharpened dental instrument. 
Later the luxation and extraction of the second maxillary 
tooth were done using a modified veterinary dental in-
strument for rodent animals (iM3® Cat. No D2001).
We continuously monitored the cardiac frequency and 
body temperature during all surgical procedures, follow-
ing the ethical standards of care for experimental animals. 
Surgical events as surgery’s length, dental fracture, residu-
al roots and alveolar lamina fracture, were recorded. 
All of pre-surgical, surgical and post-surgical cares 
were done according to NOM-062-ZOO-1999 federal 
guidelines for the use and care of laboratory animals.
Animals from each study group were euthanized by 
over exposure to CO2 at two, four and six weeks poste-
rior to dental extraction (Fig. 1). 
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Immediately after their sacrifice, samples of all animals 
was dissected, photographed, and radiographed using 
a standard dental X-ray. All samples were fixed in 10% 
buffer formaldehyde by 72 h minimum. Later all sam-
ples to posteriorly decalcify in 2% HNO3 for 48h. After 
decalcification period, all samples were embedded in 
paraffin to be cut at 5μm thick. Samples were sagittally 
sectioned. Three histological slides per sample were 
obtained and stained with hematoxylin and eosin tech-
nique to be used for histological analysis. In three ran-
dom samples per group, additionally, three central sec-
tions were stained with Masson’s trichrome for cross-
reference. We used a light microscopy (Leica DM750) 
for histological examination, and photomicrographs 
were taken using the Leica LAS-EZ software.
- Macroscopic Analysis
We obtained the follow data from the macroscopic eval-
uation of dissected maxilla: open socket, exposed bone, 
loss of adjacent teeth, and bone fracture. We used these 
data to determine the clinical presence of BRONJ as 
long as present at least three of the four conditions.
- Radiological Analysis
The X-ray images were obtained from the maxilla dis-
sected immediately sacrifice to all animals. The stand-
ardized radiological parameters for all study groups 
were 60-70kV with an exposure time of 0.24 seconds. 
X-ray images were analyzed according to Pacheco using 
the IMAGE J software® (9). All images were converted 
into an 8-bit data (256 grey levels) generating a scale 
(0-255) for each image. The value zero represented the 
lowest and 255, the highest attenuation of X-ray beams. 
Image density analyses were conducted using grey lev-
els of the animals alveolar bone tissue. 
- Histological Analysis
We considered that the distance between distal first 
molar root to mesial third molar root was the region of 
interest (ROI), and then we assessed on the hematox-
ylin-eosin & Masson’s trichrome stained sections. For 
each animal/socket, histological slide sections from the 
lingual, medial and vestibular area were evaluated; we 
considered four zones of ROI by histological features, 
and they were photographed at 40x using a binocular 
light microscope Leica DM3000 (Fig. 2). We super-
posed a grid image with 36 points on histological fields 
per histological section. The grid image comprised of 
all tooth sockets from the coronal limits adjacent to the 
gingival epithelium until the lower apical limit. 
Histological changes were evaluated using the follow-
Fig. 1. Experimental design for the study.
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ing qualitative criteria: the presence of ulcerative lesion 
with exposed and necrotic bone, osteolysis, presence of 
hyperplasia of the epithelium accompanied by inflam-
matory cell infiltration, and the presence of sequestrum 
and bacterial colonies. (6,7,12,13).
Also, we obtained quantitative data, included gingi-
val tissue repair area (Tissue, mm2), empty lacunae (#/
mm2), presence and quantity of osteoclasts (#/mm2). We 
defined osteonecrosis as a loss of more than five contig-
uous osteocytes with confluent areas of empty lacunae. 
The analysis was performed in 4 zones of ROI, stained 
with Masson’s trichrome to visualize fibrous network 
in bone marrow areas and evaluate the organization of 
bone matrix.
All measurements were performed by a blinded observ-
er previously calibrated.
- Statistical Evaluation
Data were expressed as mean ± standard derivation (SD). 
We determinate the normal distribution and homogene-
ity for data before statistical analyses. Data were then 
analyzed using ANOVA and Student’s t-test. For data 
that did not fit in the distribution of normality, we used 
the Mann-Whitney and Kruskal-Wallis tests. Values 
of p<0.05 were considered statistically significant. To 
establish possible associations between each group we 
used bivariate Xi2 tests with a 95% significance level 
(p<0.05). We used STATA 12 for Windows (StataCorp 
LP., Lakeway, Texas, USA) to analyze the data.
Results
In general, study animals tolerated the procedure well. 
Furthermore, animals showed suitable hemostasis and 
rapid recovery and no associated lesions were observed 
post anesthesia. (Fig. 3a,b)
Surgical procedure in the experimental group was long-
er than in the control group. Furthermore, dental frac-
tures occurred during the extractions, resulting in the 
presence of residual root tips and fracture of the alveo-
lar lamina or teeth extracted along with interradicular 
bone (Table 1). 
- Macroscopic Analysis
In the experimental groups, rats showed ONJ, while in 
the control groups, the dental socket, was epithelialized 
although some areas exhibited accumulation of detritus. 
In the experimental groups, we observed dental opened 
socket; large areas of exposed bone as well as fractures. 
Furthermore, at the sixth week, we observed open sock-
ets with large areas of exposed bone in the three ex-
perimental animals, while the control groups showed a 
healing dental socket cover it by epithelium. (Fig 3c,d).
Analysis of the alveolar characteristics was performed 
using Xi2 tests and showed that the differences between 
the experimental and control groups were statistically 
significant (p<0.05).
- Radiographic Analysis
This analysis revealed the presence of osteolytic lesions 
accompanied by extensive destruction and formation 
of sequestrum in experimental groups. In the control 
group, the sockets were nearly filled with mineralized 
connective tissue exhibiting normal trabecular patterns. 
In contrast, radiographs from animals treated with ZA 
displayed a lack of bone formation in alveoli (Fig 3e-f). 
Statistically, significant differences were found in bone 
density between groups (p<0.05) (Table 2).
- Histological Analysis
Histologically, the control groups showed the normal 
course of healing in extraction sockets with increase 
mineralized connective tissue. Numerous differenti-
ated osteoblasts and developing a bone matrix with a 
high percentage of osteocytes appeared on the lining 
of the socket walls and expanding to the central region 
of the socket with a centripetal pattern, and complete 
mucosal coverage. Experimental groups showed ex-
tensive ulcerative lesion accompanied by exposed and 
necrotic bone with sequestrum and bacterial colonies. 
Fig. 2. Histological Analysis. The samples of maxilla were taken by white square 
(A) and sagittally sectioned (B) in three areas of interest: vestibular (a.), middle (b.) 
and Palatine (c.); two samples from each area were evaluated in Hematoxylin and 
Eosin stain. Histological evaluation was performed in 4 zones (black squares) of 
the region of interest (ROI) randomly chosen (C).
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Fi. 3. Observation of specimens at different times. Immediately after dental extraction, the control group shows a complete extracted 
molar (a.); in contrast, the experimental group shows a fractured root (b.). The rats sacrificed at six weeks after extraction in control 
group shows complete healing of oral mucosa (c.) the experimental group shows incomplete healing of oral mucosa, showing exposed 
alveolar bone (d.). Radiographically the control group (e.) shows a linear opaque radio-density around extraction socket in contrast with 
the experimental group (f.) which shows mottled trabecular pattern around extraction socket. Histological examination of ROI at 6 weeks 
after tooth extraction. Black arrows point to areas of inflammation, yellow arrows to osteonecrosis area. The experimental group exhibit 
areas with fewer bone lacunae and areas of dead bone, the control group shows bone deposition and presence of osteocytes in an organ-
ized bone matrix.
                                                    
Surgery 
                                               features
    Study                                 observed
  Groups
Surgery Length *
Mean (SD)
Tooth
Fractures (%)
Residual 
Root (%)
Alveolar lamina
 Fracture (%)
Control Groups
Group 1 (n=6) 7.83 (±0.75) --- --- ---
Group 2 (n=6) 7.83 (±0.75) --- 16% 16%
Group 3 (n=4) 7.75 (±0.5) --- --- ---
Experimental 
Groups
Group 4 (n=6) 17.16 (±1.94) 16% 33% 33%
Group 5 (n=6) 18 (±1.89) 16% 33% 33%
Group 6 (n=4) 18 (±0.81) --- 25% 25%
Table 1. Surgery features * time, minutes.
SD: Standar Deviation-zero.
Groups Mean (±standard deviation) P value 
Second week
(n=6)
Experimental 155.83 (±2.31)
0.000*
Control 160.83 (±5.03)
Fourth week
(n=6)
Experimental 144.16 (±6.73)
0.000*
Control 171.5 (±7.12)
Sixth week
(n=4)
Experimental 138 (±2.94)
0.000*
Control 194.5 (±6.35)
Table 2. Gray level (GL) values in ROI analyzed with Student’s t-test between groups with 5% 
significance level (P<0.05).
* significant 5% 
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Inflammatory cell infiltration in the connective tissue 
was equally observed at first weeks. The morphometric 
analysis showed that the experimental groups had lower 
osteoclast number than each control group (p<0.05), 
also showed higher necrotic bone fractions and dem-
onstrated significantly higher empty lacunae (p<0.05). 
The control groups showed bone matrix with highly 
eosinophilic and organized (Fig. 3). In contrast, the 
experimental group exhibited scant, poorly organized 
bone matrix (Table 3).
 
 
                                    Histological  
                                    features 
                                      observed 
     Study  
    Groups 
Osteocyte Lacunae (%) Bone Matrix (%) Inflammatory Infiltrate (%) 
Contaminated 
Tissue (%) 
Osteonecrosis 
(%) 
Osteocytes Acellular Organized Dispersed Present Absent Present Absent Yes No 
Control 
Groups 
Group 1 (n=6) 100% --- 67% 33% 50% 50% 17% 83% --- 100% 
Group 2 (n=6) 100% --- 100 % --- 17% 83% 17% 83% --- 100% 
Group 3 (n=4) 100% --- 100% --- --- 100% 17% 83% --- 100% 
Experim
ental 
Groups 
Group 5 (n=6) --- 100% --- 100% 100% --- 100% --- 100% --- 
Group 6 (n=6) --- 100% --- 100% 100% --- 100% --- 100% --- 
Group 7 (n=4) 25% 75% --- 100% 100% --- 100% --- 100% ---  
Table 3. Histological Examination.
- zero.
Discussion 
Currently, it is necessary to obtain an animal model for a 
better understanding of pathophysiology and to develop 
standards for the prevention and treatment of BRONJ.
The aim of our study was to develop a clinically rel-
evant, inexpensive, and easily replicable animal model 
affected by BRONJ. 
We found that a short lapse dose of BP before the sur-
gical procedure develops BRONJ while other studies 
employed high doses and over longer periods of time 
(14,18,19). 
To assess the specific effects of bisphosphonate on the 
alveolar bone tissue, we treated our animals in the ab-
sence of other diseases or medications. In contrast, other 
studies concerning BRONJ have changed the metabolic 
conditions of rats by using additional bisphosphonate’s 
therapies with immunosuppressant drugs (Table 4). 
The dental extraction is the strongest risk factor for the 
development of BRONJ in patients receiving bisphos-
phonates. By extracting only the second maxillary mo-
lar we were able to produce BRONJ in the experimental 
group (See Fig. 3) (17,15,20-22), while previous studies 
had extracted all hemimandible molars to obtain the 
same result (20,22). 
The rats receiving bisphosphonates showed more sur-
gical complications than the control group (Table 1). 
Our results demonstrated that the usage of zoledronic 
acid increases the alveolar bone density. This condition 
makes the surgical procedures difficult and they require 
a longer time than usual. We also observed that the ex-
perimental group exhibit evident delayed reepitheliali-
zation at the fourth week, in contrast with other BRONJ 
models which showed the same condition but during a 
longer period of time. (2,9,22,23)
The X-Ray results showed no overlapping structures, 
radiolucent areas with a lack of bone formation (EG). 
These data were analyzed considering the grey-level 
profiles to demonstrate quantitatively assessed bone 
density in the alveolar area. Several other studies have 
used X-Ray and micro CT, but this work did quantita-
tive analyses and not only descriptive ones (11,14,17). 
We agree in our histological analysis with other studies. 
The experimental groups show decreased bone lacunae, 
osteoclastic bone surfaces, a reduced bone formation 
rate and severely affected bone matrix (9,23,24).
The previous animal studies have reported different 
rates for BRONJ development (Table 4). The success 
rate observed in the present study must be attributed 
to several factors, including the use of a high dose of 
zoledronic acid administered in a short time lapse, and 
also, the sacrifice time is not extended to show BRONJ.
This study has several strengths, including BRONJ de-
velopment in a short period, because we have signifi-
cant results at four weeks after dental extraction, thus 
reducing the suffering of animals. The high availabil-
ity, inexpensiveness, and easy handling of this animal 
model make it an excellent option for studies to research 
BRONJ pathophysiology.
Our rat model will allow contributing to conduct pro-
spective controlled studies to evaluate the different risk 
factors, etiology, prevention and treatment of BRONJ. 
Additionally, this animal model provides an additional 
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Author Bisphosphonate Used 
Bisphosphonate 
Dosage Added Drugs 
Route Of 
Administration 
Animal 
Used 
Surgical 
Intervention 
Rate Of 
Osteonecrosis 
Sonis et al. 
(20) 2009  Zoledronate 0.075 mg/kg/day 
Dexamethason
e 
1 mg/kg/7 days 
SC Rats 
Tooth 
extraction from 
maxilla and 
mandible 
Zol: 60% 
Zol/Dex: 60-
100%b 
Burr et al. 
(25) 2009  
Alendronate/ 
Zoledronate 
Alendronate, 0.2 
or 1.0 mg/kg/day 
for 1 or 3 years 
and 
Zoledronate 0.06 
mg/kg/day for 6 
months 
- OR/IV Dogs -- 
17–25% one 
year 
25–33% for 
three years 
with ALN 
Zol: not 
especific 
López-Jornet 
et al. (22) 
2010  
Pamidronate 0.03 mg/kg/day 
Dexamethason
e 
1 mg/kg/day 
IV Rats 
Tooth 
extraction from 
maxilla and 
mandible 
Pam: 0% 
Pam/Dex: 30% 
Bi et al.  
(14) 2010  Zoledronate 
0.125 mg/kg/3.5 
days 
Dexamethason
e 
5 mg/kg/7 days 
Docetaxel 
25 mg/kg/7 
days 
IP Mice 
Tooth 
extraction from 
maxilla and 
mandible 
Zol: 0% 
Zol/Dex: 27% 
Zol/Dex/Doc: 
100%c 
Aghaloo et al. 
(18) 2011  Zoledronate 
4-mg/60-kg three 
times per week 
for 3 weeks 
- IP Rats Periodontal lesion Zol: 47% 
Pautke et al. 
(17) 2012  Zoledronate 0.05 mg /kg - IV 
Miniature 
pigs 
Tooth 
extraction from 
maxilla and 
mandible 
Zol: 57% 
Bonnet et al. 
(15) 2013  Zoledronate 
100 !g/kg/month 
and 100 
!g/kg/week for 3 
months 
- IV Mice Periodontal disease Zol: 60% 
Aghaloo et al. 
(21) 2014  Zoledronate 
4-mg/60-kg three 
times per week 
for 3 weeks 
- IP Mice Peri-radicular lesion Zol: 47% 
 
Table 4. Animal models to study osteonecrosis of the jaw related to bisphosphonate treatment..
- no added drugs
-- no surgical intervention
IV: intravenously
IP: intraperitoneally
SC: subcutaneous
useful, practical, and cost-effective model to develop 
new therapeutic strategies to cure this particular side 
effects in human. 
Recently, a new side effect has been described, Medica-
tion-Related Osteonecrosis in Jaws (MROJ). We appre-
ciate that our study is limited to one type of antiresorp-
tive medication, acid zoledronic. However, it is enough 
to develop BRONJ. Thus, our research group considers 
that is necessary to develop animal models using other 
antiangiogenic and antiresorptive agents such as deno-
sumab and bevacizumab.
Finally, in the model involving the extraction of the sec-
ond maxillary molar of rats treated with two zoledronic 
acid doses of 0.06mg/kg per two weeks, osteonecrosis 
lesions were found in all cases. The model has to be 
used to analyze the changes occurring in the tissues in-
volved in the extraction at around six weeks; it is no 
necessary the extension of the study beyond this time. 
BRONJ studies have been based on case reviews and 
animal studies.
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